【摘要】 目的 〖JP2〗探討血管內(nèi)皮生長因子（VEGF）聯(lián)合血清腫瘤標志物對肺癌早期診斷意義。 方法 2008年1月-〖JP〗2009年8月收治的92例患者中肺癌患者64例，采集靜脈血清標本采用酶聯(lián)免疫法檢測其VEGF水平。 結(jié)果 64例肺癌與28例非肺癌患者VEGF表達水平分別為（255.72±566.00）、（299.46±795.8） pg/mL，兩者比較無統(tǒng)計學意義（P gt;0.05）；43例中晚期肺癌VEGF值（125.07±68.2） pg/mL，表達顯著高于12例早期肺癌（196.00±260.60） pg/mL （P lt;0.05）；CEA與CYFRA21-1的表達對判斷26例發(fā)生胸膜轉(zhuǎn)移的肺癌有統(tǒng)計學意義（P lt;0.05）。 結(jié)論 結(jié)合血清VEGF水平和常規(guī)腫瘤標志物，可評估現(xiàn)狀及臨床分期，VEGF結(jié)合CEA與CYFRA21-1表達水平為預測肺癌患者早期發(fā)生胸膜轉(zhuǎn)移提供理論依據(jù)。
【Abstract】 Objective To evaluate the effect of combined detection value of serum vascular endothelial growth factor (VEGF) and tumor markers on early diagnosis of lung cancer. Method Intravenous serum levels of VEGF and tumor markers were assayed by ELISA in 92 patients including 64 lung cancer from January 2008 to August 2009. Results The difference in serum levels of VEGF between the 64 patients with lung cancer [(255.72±566.0) pg/mL] and 28 health adult [(299.46±795.8) pg/mL] was not significant (P gt;0.05). The level of VEGF in 43 patients with middle and late lung cancer [(125.07±68.2) pg/mL] was significantly higher than that in the 12 patients with early lung cancer [(196.00±260.60) pg/mL] (P lt;0.05). There were statistical significance in expression of serum CEA and CYFRA21-1 on diagnosis in 26 patients having lung cancer with early metastasis pleural fluid (P lt;0.05). Conclusion Combined diagnostic of serum VEGF and tumor markers can assess the state of an illness and clinical stage, and the serum levels of serum VEGF,CEA and CYFRA21-1 may be a good predictor for lung cancer with early metastasis pleural fluid.
引用本文： 李艷萍,包勇,何萍,梁秋萍. 血管內(nèi)皮生長因子聯(lián)合血清腫瘤標志物對肺癌早期診斷意義. 華西醫(yī)學, 2010, 25(10): 1808-1810. doi: 復制
| 1. | Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells[J]. Biochem Biophys Res Commun, 1989, 161(2)∶851-858. |
| 2. | Tomoda M, Maehara Y, Kakeji Y, et al. Intratumoral neovascu-larization and growth pattern in early gastric carcinoma[J]. Cancer, 1999, 85(11)∶2340-2346. |
| 3. | Katsabeki-Katsafli A, Kerenidi T, Kostikas K, et al. Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer[J]. Lung Cancer, 2008, 60: 271-276. |
| 4. | 郭光祖, 徐洪波. 血清VEGF和EGF檢測對肺癌患者的臨床意義[J]. 中國醫(yī)藥指南, 2009, 5(7): 32-33. |
| 5. | Sheng H, AOE M, Doihara H, et al. Prognostic value of vascular endothelial growth factor expression in primary lung carcinoma[J]. Acta Med Okayama, 2000, 54(3): 119-126. |
| 6. | Fan XH, Han BH, Dong QG, et al. Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma[J]. Chin J Tuberc Respir Dis, 2003, 26(9): 539-543. |
| 7. | Tabernero J. The role of VEGF and EGFR inhibition: implication for combining anti-VEGF and anti-EGFR agents[J]. Mol Cancer Res, 2007, 5: 203-220. |
| 8. | 金陽, 高巖, 蘇遠, 等. 非小細胞肺癌患者血清血管內(nèi)皮生長因子和基質(zhì)金屬蛋白酶-9水平的變化[J]. 華中科技大學學報醫(yī)學版, 2006, 35, 328-330. |
| 9. | 王水利, 王茁, 羅小峰. 小細胞肺癌患者血清血管內(nèi)皮生長因子含量水平的臨床意義[J]. 現(xiàn)代腫瘤醫(yī)學, 2006, 14, 810-812. |
| 10. | 陳一偉, 呂同德, 高煒. 肺癌患者手術(shù)前后血清TNF、EGF含量的臨床觀察[J]. 放射免疫學雜志[J], 2006, 19, 135-136. |
| 11. | Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and over expression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung cancer[J]. Br J Cancer, 2002, 86(4): 558-563. |
| 12. | 葉超然. 血管內(nèi)皮生長因子在非小細胞肺癌的表達及其意義[J]. 廣西醫(yī)科大學學報, 2001, 18(4): 478-479. |
| 13. | 沙云風, 季之森. 非小細胞肺癌患者血清VEGF、CYFRA21-1及CEA的表達及意義[J]. 醫(yī)學檢驗與臨床, 2009, 4: 29-31. |
| 14. | 李艷萍, 包勇, 殷俊. CYFRA211與TGF-β1聯(lián)合檢測診斷良惡性胸腔積液的意義[J]. 西部醫(yī)學, 2008, 3(20): 523-524. |
| 15. | Cressey R, Wattananupong O, Lertprasertsuke N, et al. Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tuMourigenesis[J]. BMC Cancer, 2005, 5(2): 128-134. |
- 1. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells[J]. Biochem Biophys Res Commun, 1989, 161(2)∶851-858.
- 2. Tomoda M, Maehara Y, Kakeji Y, et al. Intratumoral neovascu-larization and growth pattern in early gastric carcinoma[J]. Cancer, 1999, 85(11)∶2340-2346.
- 3. Katsabeki-Katsafli A, Kerenidi T, Kostikas K, et al. Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer[J]. Lung Cancer, 2008, 60: 271-276.
- 4. 郭光祖, 徐洪波. 血清VEGF和EGF檢測對肺癌患者的臨床意義[J]. 中國醫(yī)藥指南, 2009, 5(7): 32-33.
- 5. Sheng H, AOE M, Doihara H, et al. Prognostic value of vascular endothelial growth factor expression in primary lung carcinoma[J]. Acta Med Okayama, 2000, 54(3): 119-126.
- 6. Fan XH, Han BH, Dong QG, et al. Vascular endothelial growth factor inhibits dendritic cells from patients with non-small cell lung carcinoma[J]. Chin J Tuberc Respir Dis, 2003, 26(9): 539-543.
- 7. Tabernero J. The role of VEGF and EGFR inhibition: implication for combining anti-VEGF and anti-EGFR agents[J]. Mol Cancer Res, 2007, 5: 203-220.
- 8. 金陽, 高巖, 蘇遠, 等. 非小細胞肺癌患者血清血管內(nèi)皮生長因子和基質(zhì)金屬蛋白酶-9水平的變化[J]. 華中科技大學學報醫(yī)學版, 2006, 35, 328-330.
- 9. 王水利, 王茁, 羅小峰. 小細胞肺癌患者血清血管內(nèi)皮生長因子含量水平的臨床意義[J]. 現(xiàn)代腫瘤醫(yī)學, 2006, 14, 810-812.
- 10. 陳一偉, 呂同德, 高煒. 肺癌患者手術(shù)前后血清TNF、EGF含量的臨床觀察[J]. 放射免疫學雜志[J], 2006, 19, 135-136.
- 11. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and over expression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung cancer[J]. Br J Cancer, 2002, 86(4): 558-563.
- 12. 葉超然. 血管內(nèi)皮生長因子在非小細胞肺癌的表達及其意義[J]. 廣西醫(yī)科大學學報, 2001, 18(4): 478-479.
- 13. 沙云風, 季之森. 非小細胞肺癌患者血清VEGF、CYFRA21-1及CEA的表達及意義[J]. 醫(yī)學檢驗與臨床, 2009, 4: 29-31.
- 14. 李艷萍, 包勇, 殷俊. CYFRA211與TGF-β1聯(lián)合檢測診斷良惡性胸腔積液的意義[J]. 西部醫(yī)學, 2008, 3(20): 523-524.
- 15. Cressey R, Wattananupong O, Lertprasertsuke N, et al. Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tuMourigenesis[J]. BMC Cancer, 2005, 5(2): 128-134.